News
- Author:
- Patrice Wendling
Publish date: November 29, 2022
A substudy of the VITAL trial provides the first randomized data examining the effect of the popular supplement on muscle symptoms in statin users....
News
- Author:
- Patrice Wendling
Publish date: November 18, 2022
The novel agent lowers aldosterone activity without the off-target inhibition of cortisol synthesis that has thwarted previous drug candidates, the...
News
- Author:
- Patrice Wendling
Publish date: November 7, 2022
Treatment with tongxinluo was tied to better outcomes out to 1 year, but observers say further data are needed to see how it may fit into STEMI car...
News
- Author:
- Patrice Wendling
Publish date: November 6, 2022
A phase 1 study showed robust responses in patients with TTR amyloidosis with cardiomyopathy, similar to those reported last year in amyloid polyne...
News
- Author:
- Patrice Wendling
Publish date: November 3, 2022
A national analysis found that only one-third of hospitals are utilizing the assays, despite the first test being approved in 2017.
News
- Author:
- Patrice Wendling
Publish date: October 26, 2022
White adults were twice as likely as Black adults to receive a ventricular assist device or heart transplant.
News
- Author:
- Patrice Wendling
Publish date: October 17, 2022
The review tackles potential drug-drug interactions with the antiviral drug and today’s most commonly prescribed cardiovascular drugs.
News
- Author:
- Patrice Wendling
Publish date: October 14, 2022
A pilot study spotlights differences in two common biomarkers of cardiac disease as well as the need for greater inclusivity in cardiovascular tria...
News
- Author:
- Patrice Wendling
Publish date: September 27, 2022
Outcomes once deemed “almost too good to be true” disappeared with longer follow-up in an all-comer population of patients with diabetes undergoing...
News
- Author:
- Patrice Wendling
Publish date: September 23, 2022
Longer follow-up from the Amulet IDE shows largely comparable results, but also distinct trends for each device in patients with atrial fibrillatio...
News
- Author:
- Patrice Wendling
Publish date: September 15, 2022
“People with rheumatic arthritis, when they have a heart attack, are less likely to get the standard kind of treatments and have worse outcomes.”
News
- Author:
- Patrice Wendling
Publish date: September 9, 2022
Letters sent Sept. 8 by the FDA and Abbott Vascular, the device manufacturer, warn about an increase in reports that the device’s clip lock can mal...
News
- Author:
- Patrice Wendling
Publish date: August 31, 2022
Chief among the benefits was a reduction in cardiovascular mortality not observed in the pivotal trial that led to U.S. approval of evolocumab.
News
- Author:
- Patrice Wendling
Publish date: August 28, 2022
A striking and unexpected reduction in death with the use of predominantly warfarin was just one of the many surprises delivered by the INVICTUS tr...
News
- Author:
- Patrice Wendling
Publish date: August 27, 2022
The surprising results of REVIVED-BCIS2 are likely to leave in place current guidelines for heart failure and revascularization.
